InvestorsHub on MSN

Soligenix secures EU orphan drug designation for Behçet’s disease therapy

Soligenix Inc. (NASDAQ:SNGX) said the European Commission has granted orphan drug designation to dusquetide, the active ...

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
Nasdaq

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Nasdaq

Soligenix Reports Promising Phase 2a Results For SGX945 In Behçet's Disease

(RTTNews) - Shares of Soligenix Inc. (SNGX) are up more than 20% at $1.50 in premarket hours, following encouraging results from its Phase 2a proof of concept study of SGX945 in the treatment of ...
Morningstar

Soligenix Shares Surge on FDA Orphan Designation in Behcet's

Soligenix shares surged more than 50% in early trading Monday after the late-stage biopharmaceutical company won U.S. Food and Drug Administration orphan-drug designation for the active ingredient in ...
Morningstar

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
KTLA

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...